Clinical Trial Update: Define the Optimal Uptake Time of 68Ga-OPS202 When Used as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Newly Diagnosed Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating the optimal uptake time of 68Ga-OPS202 as a PET imaging agent in newly diagnosed breast cancer; study status terminated wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• 68Ga-OPS202

Snippet

Sponsor: Ipsen | Conditions: Breast Cancer | Phase 2 | Status: TERMINATED | Results posted: 2020-09-07